Calistoga series C raises $40 million to advance pipeline
This article was originally published in Scrip
Executive Summary
Calistoga Pharmaceuticals, a US company focused on isoform-selective PI3 kinase inhibitors for the treatment of cancer and inflammatory diseases, has raised $40 million in a series C financing to advance its development pipeline.